We are excited to announce the merger of Syner-G BioPharma Group and Sequoia Biotech Consulting, joining forces to deliver integrated solutions for life sciences.
Read the Press Release | Learn more about Sequoia
We are the world's leading CMC, Regulatory Affairs, and Medical Writing solutions provider for biopharma.
About Syner-g
Who We Are
What We Do
Pharmaceutical Development (CMC)
Pharmaceutical Development (CMC)
Regulatory Strategy & Submissions
Regulatory Strategy & Submissions
Functional Outsourcing Partnerships
Functional Outsourcing Partnerships
Medical Writing
Medical Writing
Quality & Compliance
Quality & Compliance
Our Capabilities
Why Syner-G?
Number of Years of Industry Experienced Sr. Consultants
Number of Employee and
Number of Ph.Ds World-wide
Number of INDs and IND Amendments Filed
Number of Post-Approval Major Supplements
Years As An Organization (aggregate across all Syner-G companies)
Assets Supported
Number of Agency Meetings
Careers
Latest Developments and Insights
The Path to Breakthrough Therapies: A Comprehensive Guide to Drug Development
The submission of an IND or other global first-in-human regulatory filing represents a pivotal milestone in transforming scientific discoveries, known as new chemical entities, into potential medical breakthroughs. This process involves a comprehensive evaluation of drug candidates to ensure their…
Read Full Article
What is Process Control and Why is it Important?
What is process control? Process control is the backbone of precision in manufacturing, providing the framework needed to maintain quality, safety, and efficiency. In the biopharmaceutical industry, even minor deviations can have significant consequences; process control plays a vital role…
Read Full Article
BLA vs. NDA: Understanding the Differences in Biopharmaceutical Approvals
Navigating the regulatory landscape is a critical step in the development of biopharmaceutical products. Biologics License Applications (BLAs) and New Drug Applications (NDAs) are two distinct drug marketing applications and approval pathways designed for biologics and small-molecule drugs (traditional drug…